CureVac NV (CVAC)vsJohnson & Johnson (JNJ)
CVAC
CureVac NV
$4.66
0.00%
HEALTHCARE · Cap: $1.05B
JNJ
Johnson & Johnson
$255.88
-3.63%
HEALTHCARE · Cap: $615.36B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 138333% more annual revenue ($97.93B vs $70.74M). CVAC leads profitability with a 182.1% profit margin vs 21.5%. CVAC trades at a lower P/E of 7.0x. JNJ earns a higher WallStSmart Score of 57/100 (C).
CVAC
Buy56
out of 100
Grade: C
JNJ
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+63.5%
Fair Value
$12.77
Current Price
$4.66
$8.11 discount
Intrinsic value data unavailable for JNJ.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 182 of every $100 in revenue as profit
Strong operational efficiency at 573.0%
Safe zone — low bankruptcy risk
Every $100 of equity generates 22 in profit
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 28.6%
Generating 3.4B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Revenue declined 89.0%
Moderate valuation
Expensive relative to growth rate
Earnings declined 1.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : CVAC
The strongest argument for CVAC centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 182.1% and operating margin at 573.0%.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 28.6%.
Bear Case : CVAC
The primary concerns for CVAC are Market Cap, Revenue Growth.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
CVAC profiles as a declining stock while JNJ is a mature play — different risk/reward profiles.
CVAC carries more volatility with a beta of 1.84 — expect wider price swings.
JNJ is growing revenue faster at 6.6% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 56/100), backed by strong 21.5% margins. CVAC offers better value entry with a 63.5% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CureVac NV
HEALTHCARE · BIOTECHNOLOGY · USA
CureVac NV, a clinical-stage biopharmaceutical company, is focused on developing various transformative drugs based on messenger ribonucleic acid (mRNA). The company is headquartered in Tbingen, Germany.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?